ASH 2020 Multiple Myeloma In-depth

Complete Coverage

TOURMALINE-MM2: Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM

A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.

Hospitalization Burden of Patients with Multiple Myeloma

Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.

Fully Human BCMA-Directed CAR-T Shows High Response Rate in Myeloma

A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.

CAR-T Product With Unique Manufacturing Process Appears Safe in the Outpatient Setting

A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.

BCMA-Directed CAR-T Therapy Shows Clinical Activity in Multiple Myeloma

A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.

Treatment With High-Dose Melphalan Linked to Mutational Load in Multiple Myeloma

Dr Samur and colleagues found that high-dose melphalan caused an approximately 2.5-fold greater mutation accumulation rate than that observed with RVD treatment alone.